As obesity management medications explode in popularity, obesity experts issue caution on who should prescribe them

The popularity of glucagon-like peptide-1 (GLP-1) agonists like Ozempic, Wegovy and Mounjaro has exploded in recent years. Initially approved to treat Type 2 diabetes, the drugs have become the tool of choice for millions of Americans, including influential celebrities, who wish to slim down. A recent survey even suggests that 1 in 8 Americans have received a prescription for them.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup